{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tirzepatide-muscle-loss","title":"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition","body":"## What's breaking down\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\n\n## Why Tirzepatide might help you\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\n\n## How these fit together\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\n\n## What the evidence actually shows\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct catabolic effect on muscle beyond caloric deficit.\n\n## What scientists say\nReview analyses note lean mass loss with tirzepatide aligns with weight reduction magnitude and is not exaggerated versus other GLP-1 agents when proportions are examined; some data suggest improved muscle quality via reduced intramuscular fat (mechanistic + human tier).\n\n## What people say on Reddit\nUsers report variable DEXA outcomes; several note that consistent resistance training and higher protein intake appear to limit lean mass decline, while others observe typical proportional loss during 20-30+ lb reductions. Anecdotes emphasize individual factors like training status over drug-specific effects (anecdotal tier).\n\n## What people say on X\nPosts citing SURMOUNT-1 data highlight the 75/25 fat-to-lean split as expected rather than alarming; some users share personal scans showing maintained or improved strength metrics alongside weight loss (anecdotal tier).\n\n## What we do not know\nLong-term (>72 weeks) functional outcomes such as strength, mobility, or sarcopenia risk in older adults remain under-studied in dedicated human trials. Direct head-to-head comparisons of muscle quality preservation strategies (protein dosing, exercise timing) with tirzepatide are limited.\n\n## Safety and limits\nHuman trial adverse events were primarily gastrointestinal; body composition shifts occurred alongside substantial fat loss. Individual monitoring of lean mass via DEXA or functional tests is discussed in literature when rapid weight reduction is underway. All data are observational within weight-loss contexts; no causal claims for muscle preservation or harm.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In SURMOUNT-1 DXA substudy, tirzepatide produced 21.3% weight loss with 33.9% fat mass reduction and 10.9% lean mass reduction at 72 weeks; ~75% of lost weight was fat and 25% lean, identical proportion to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Core human evidence separating fat vs lean loss proportions during tirzepatide treatment.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SURPASS-3 MRI substudy found tirzepatide-associated muscle volume reduction matched expected changes from weight loss, while muscle fat infiltration decreased more than population-based estimates.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Shows muscle quality improvement alongside volume adaptation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users describe variable lean mass outcomes on tirzepatide; training and protein intake frequently cited as modifiers of loss magnitude.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996356/","title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study","quote":"The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively... Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.","summary":"DXA substudy results showing proportional composition changes.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"59d23763d41c6d5b347c0e21eddb32776e55119bb4c2aa3533d2bd1f84c09089"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40318682/","title":"Tirzepatide and muscle composition changes in people with type 2 diabetes","quote":"observed muscle volume changes across all tirzepatide doses were similar to population-based estimated changes... observed reductions in muscle fat infiltration... were significantly greater than population-based estimates","summary":"MRI data on muscle volume and fat infiltration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"59d23763d41c6d5b347c0e21eddb32776e55119bb4c2aa3533d2bd1f84c09089","hash":"541d593b724d09c85909001b024036cd06041f326642fb3d7569e727cfdd4408"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Zepbound/comments/1kg1gm0/tirz_and_muscle_mass/","title":"Tirz and muscle mass","quote":"Using MRI, the authors found that muscle fat decreased in the Tirz groups, without a decrease in actual 'muscle'.","summary":"User discussion referencing trial MRI findings and personal experience.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"541d593b724d09c85909001b024036cd06041f326642fb3d7569e727cfdd4408","hash":"155806350e6fd84d1a09b457a9fe10aeb4c4d5f0f94d34f005efbbc5c1debb61"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:45:59.086Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition","register":"source_ledger","body":"## What's breaking down\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\n\n## Why Tirzepatide might help you\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\n\n## How these fit together\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\n\n## What the evidence actually shows\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct catabolic effect on muscle beyond caloric deficit.\n\n## What scientists say\nReview analyses note lean mass loss with tirzepatide aligns with weight reduction magnitude and is not exaggerated versus other GLP-1 agents when proportions are examined; some data suggest improved muscle quality via reduced intramuscular fat (mechanistic + human tier).\n\n## What people say on Reddit\nUsers report variable DEXA outcomes; several note that consistent resistance training and higher protein intake appear to limit lean mass decline, while others observe typical proportional loss during 20-30+ lb reductions. Anecdotes emphasize individual factors like training status over drug-specific effects (anecdotal tier).\n\n## What people say on X\nPosts citing SURMOUNT-1 data highlight the 75/25 fat-to-lean split as expected rather than alarming; some users share personal scans showing maintained or improved strength metrics alongside weight loss (anecdotal tier).\n\n## What we do not know\nLong-term (>72 weeks) functional outcomes such as strength, mobility, or sarcopenia risk in older adults remain under-studied in dedicated human trials. Direct head-to-head comparisons of muscle quality preservation strategies (protein dosing, exercise timing) with tirzepatide are limited.\n\n## Safety and limits\nHuman trial adverse events were primarily gastrointestinal; body composition shifts occurred alongside substantial fat loss. Individual monitoring of lean mass via DEXA or functional tests is discussed in literature when rapid weight reduction is underway. All data are observational within weight-loss contexts; no causal claims for muscle preservation or harm.","claims":[{"id":"c1","text":"In SURMOUNT-1 DXA substudy, tirzepatide produced 21.3% weight loss with 33.9% fat mass reduction and 10.9% lean mass reduction at 72 weeks; ~75% of lost weight was fat and 25% lean, identical proportion to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Core human evidence separating fat vs lean loss proportions during tirzepatide treatment.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SURPASS-3 MRI substudy found tirzepatide-associated muscle volume reduction matched expected changes from weight loss, while muscle fat infiltration decreased more than population-based estimates.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Shows muscle quality improvement alongside volume adaptation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users describe variable lean mass outcomes on tirzepatide; training and protein intake frequently cited as modifiers of loss magnitude.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996356/","title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study","quote":"The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively... Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40318682/","title":"Tirzepatide and muscle composition changes in people with type 2 diabetes","quote":"observed muscle volume changes across all tirzepatide doses were similar to population-based estimated changes... observed reductions in muscle fat infiltration... were significantly greater than population-based estimates","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Zepbound/comments/1kg1gm0/tirz_and_muscle_mass/","title":"Tirz and muscle mass","quote":"Using MRI, the authors found that muscle fat decreased in the Tirz groups, without a decrease in actual 'muscle'.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":20535,"tokens_out":2677,"cost":0.03236125,"prev_hash":"genesis","hash":"a2034708a66ebf71d42e46229c3772775b26bc380402f55bd3143ab5d5375e24"}],"provenance":[{"ts":"2026-06-29T22:45:59.086Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Muscle Loss\nSlug: tirzepatide-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your conditio","response":"{\n  \"slug\": \"tirzepatide-muscle-loss\",\n  \"title\": \"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition\",\n  \"body\": \"## What's breaking down\\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\\n\\n## Why Tirzepatide might help you\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\\n\\n## How these fit together\\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\\n\\n## What the evidence actually shows\\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct cataboli","tokens_in":20535,"tokens_out":2677,"cost":0,"prev":"genesis","hash":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51"},{"ts":"2026-07-17T02:43:17.561Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51","hash":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"}],"energy":{"passes":2,"tokens_in":20535,"tokens_out":2677,"tokens_total":23212,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"},"posted_at":"2026-06-29T21:33:45.542Z","created_at":"2026-06-29T21:33:45.542Z","updated_at":"2026-07-17T02:43:17.561Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide-muscle-loss","json":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss","bundle":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide-muscle-loss","json":"/api/articles/tirzepatide-muscle-loss","markdown":"/api/articles/tirzepatide-muscle-loss/bundle?format=markdown","skill":"/api/articles/tirzepatide-muscle-loss/skill","topology":"/api/articles/tirzepatide-muscle-loss/topology","versions":"/api/articles/tirzepatide-muscle-loss/revisions","invocations":"/api/articles/tirzepatide-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tirzepatide-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1fce0bb7932cdbb19375ee015bbe5ed12a42abd105baa2d9c895742b8a10984c","object":{"object_type":"article-object","identity":{"id":"article:tirzepatide-muscle-loss","slug":"tirzepatide-muscle-loss","title":"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tirzepatide-muscle-loss","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tirzepatide-muscle-loss/skill","role":"direct behavior","audience":"model","content":"---\nname: tirzepatide-muscle-loss\ndescription: Apply the Tirzepatide and Muscle Loss: Human Trial Data on Body Composition article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tirzepatide and Muscle Loss: Human Trial Data on Body Composition\n\nThis Skill is the behavioral expression of [the canonical article](/a/tirzepatide-muscle-loss). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tirzepatide-muscle-loss.\n- Read claims and relationships at /api/articles/tirzepatide-muscle-loss/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Rapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with h\n\n## Representations\n\n- Human: /a/tirzepatide-muscle-loss\n- JSON: /api/articles/tirzepatide-muscle-loss\n- Relationships: /api/articles/tirzepatide-muscle-loss/topology\n- History: /api/articles/tirzepatide-muscle-loss/revisions\n"},"json":{"route":"/api/articles/tirzepatide-muscle-loss","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tirzepatide-muscle-loss/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tirzepatide","muscle","loss"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tirzepatide-muscle-loss/invocations?status=success","failure_events":"/api/articles/tirzepatide-muscle-loss/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tirzepatide-muscle-loss","title":"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition","body":"## What's breaking down\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\n\n## Why Tirzepatide might help you\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\n\n## How these fit together\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\n\n## What the evidence actually shows\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct catabolic effect on muscle beyond caloric deficit.\n\n## What scientists say\nReview analyses note lean mass loss with tirzepatide aligns with weight reduction magnitude and is not exaggerated versus other GLP-1 agents when proportions are examined; some data suggest improved muscle quality via reduced intramuscular fat (mechanistic + human tier).\n\n## What people say on Reddit\nUsers report variable DEXA outcomes; several note that consistent resistance training and higher protein intake appear to limit lean mass decline, while others observe typical proportional loss during 20-30+ lb reductions. Anecdotes emphasize individual factors like training status over drug-specific effects (anecdotal tier).\n\n## What people say on X\nPosts citing SURMOUNT-1 data highlight the 75/25 fat-to-lean split as expected rather than alarming; some users share personal scans showing maintained or improved strength metrics alongside weight loss (anecdotal tier).\n\n## What we do not know\nLong-term (>72 weeks) functional outcomes such as strength, mobility, or sarcopenia risk in older adults remain under-studied in dedicated human trials. Direct head-to-head comparisons of muscle quality preservation strategies (protein dosing, exercise timing) with tirzepatide are limited.\n\n## Safety and limits\nHuman trial adverse events were primarily gastrointestinal; body composition shifts occurred alongside substantial fat loss. Individual monitoring of lean mass via DEXA or functional tests is discussed in literature when rapid weight reduction is underway. All data are observational within weight-loss contexts; no causal claims for muscle preservation or harm.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In SURMOUNT-1 DXA substudy, tirzepatide produced 21.3% weight loss with 33.9% fat mass reduction and 10.9% lean mass reduction at 72 weeks; ~75% of lost weight was fat and 25% lean, identical proportion to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Core human evidence separating fat vs lean loss proportions during tirzepatide treatment.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SURPASS-3 MRI substudy found tirzepatide-associated muscle volume reduction matched expected changes from weight loss, while muscle fat infiltration decreased more than population-based estimates.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Shows muscle quality improvement alongside volume adaptation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users describe variable lean mass outcomes on tirzepatide; training and protein intake frequently cited as modifiers of loss magnitude.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996356/","title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study","quote":"The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively... Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.","summary":"DXA substudy results showing proportional composition changes.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"59d23763d41c6d5b347c0e21eddb32776e55119bb4c2aa3533d2bd1f84c09089"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40318682/","title":"Tirzepatide and muscle composition changes in people with type 2 diabetes","quote":"observed muscle volume changes across all tirzepatide doses were similar to population-based estimated changes... observed reductions in muscle fat infiltration... were significantly greater than population-based estimates","summary":"MRI data on muscle volume and fat infiltration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"59d23763d41c6d5b347c0e21eddb32776e55119bb4c2aa3533d2bd1f84c09089","hash":"541d593b724d09c85909001b024036cd06041f326642fb3d7569e727cfdd4408"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Zepbound/comments/1kg1gm0/tirz_and_muscle_mass/","title":"Tirz and muscle mass","quote":"Using MRI, the authors found that muscle fat decreased in the Tirz groups, without a decrease in actual 'muscle'.","summary":"User discussion referencing trial MRI findings and personal experience.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:45:57.965Z","link_status":"ok","quote_status":"unverified","prev":"541d593b724d09c85909001b024036cd06041f326642fb3d7569e727cfdd4408","hash":"155806350e6fd84d1a09b457a9fe10aeb4c4d5f0f94d34f005efbbc5c1debb61"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:45:59.086Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition","register":"source_ledger","body":"## What's breaking down\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\n\n## Why Tirzepatide might help you\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\n\n## How these fit together\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\n\n## What the evidence actually shows\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct catabolic effect on muscle beyond caloric deficit.\n\n## What scientists say\nReview analyses note lean mass loss with tirzepatide aligns with weight reduction magnitude and is not exaggerated versus other GLP-1 agents when proportions are examined; some data suggest improved muscle quality via reduced intramuscular fat (mechanistic + human tier).\n\n## What people say on Reddit\nUsers report variable DEXA outcomes; several note that consistent resistance training and higher protein intake appear to limit lean mass decline, while others observe typical proportional loss during 20-30+ lb reductions. Anecdotes emphasize individual factors like training status over drug-specific effects (anecdotal tier).\n\n## What people say on X\nPosts citing SURMOUNT-1 data highlight the 75/25 fat-to-lean split as expected rather than alarming; some users share personal scans showing maintained or improved strength metrics alongside weight loss (anecdotal tier).\n\n## What we do not know\nLong-term (>72 weeks) functional outcomes such as strength, mobility, or sarcopenia risk in older adults remain under-studied in dedicated human trials. Direct head-to-head comparisons of muscle quality preservation strategies (protein dosing, exercise timing) with tirzepatide are limited.\n\n## Safety and limits\nHuman trial adverse events were primarily gastrointestinal; body composition shifts occurred alongside substantial fat loss. Individual monitoring of lean mass via DEXA or functional tests is discussed in literature when rapid weight reduction is underway. All data are observational within weight-loss contexts; no causal claims for muscle preservation or harm.","claims":[{"id":"c1","text":"In SURMOUNT-1 DXA substudy, tirzepatide produced 21.3% weight loss with 33.9% fat mass reduction and 10.9% lean mass reduction at 72 weeks; ~75% of lost weight was fat and 25% lean, identical proportion to placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Core human evidence separating fat vs lean loss proportions during tirzepatide treatment.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SURPASS-3 MRI substudy found tirzepatide-associated muscle volume reduction matched expected changes from weight loss, while muscle fat infiltration decreased more than population-based estimates.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Shows muscle quality improvement alongside volume adaptation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users describe variable lean mass outcomes on tirzepatide; training and protein intake frequently cited as modifiers of loss magnitude.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:45:58.352Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996356/","title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study","quote":"The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively... Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40318682/","title":"Tirzepatide and muscle composition changes in people with type 2 diabetes","quote":"observed muscle volume changes across all tirzepatide doses were similar to population-based estimated changes... observed reductions in muscle fat infiltration... were significantly greater than population-based estimates","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Zepbound/comments/1kg1gm0/tirz_and_muscle_mass/","title":"Tirz and muscle mass","quote":"Using MRI, the authors found that muscle fat decreased in the Tirz groups, without a decrease in actual 'muscle'.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":20535,"tokens_out":2677,"cost":0.03236125,"prev_hash":"genesis","hash":"a2034708a66ebf71d42e46229c3772775b26bc380402f55bd3143ab5d5375e24"}],"provenance":[{"ts":"2026-06-29T22:45:59.086Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Muscle Loss\nSlug: tirzepatide-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your conditio","response":"{\n  \"slug\": \"tirzepatide-muscle-loss\",\n  \"title\": \"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition\",\n  \"body\": \"## What's breaking down\\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\\n\\n## Why Tirzepatide might help you\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\\n\\n## How these fit together\\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\\n\\n## What the evidence actually shows\\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct cataboli","tokens_in":20535,"tokens_out":2677,"cost":0,"prev":"genesis","hash":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51"},{"ts":"2026-07-17T02:43:17.561Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51","hash":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"}],"energy":{"passes":2,"tokens_in":20535,"tokens_out":2677,"tokens_total":23212,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"},"posted_at":"2026-06-29T21:33:45.542Z","created_at":"2026-06-29T21:33:45.542Z","updated_at":"2026-07-17T02:43:17.561Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide-muscle-loss","json":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss","bundle":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide-muscle-loss","json":"/api/articles/tirzepatide-muscle-loss","markdown":"/api/articles/tirzepatide-muscle-loss/bundle?format=markdown","skill":"/api/articles/tirzepatide-muscle-loss/skill","topology":"/api/articles/tirzepatide-muscle-loss/topology","versions":"/api/articles/tirzepatide-muscle-loss/revisions","invocations":"/api/articles/tirzepatide-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tirzepatide-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"1fce0bb7932cdbb19375ee015bbe5ed12a42abd105baa2d9c895742b8a10984c"}}}